Photo via The Guardian

FDA scientists opposed Trump administration’s move to ease peptide access

Read the original at The Guardian ↗
Cite

Associated Press. (2026, October 28). FDA scientists opposed Trump administration’s move to ease peptide access. The Guardian. https://www.theguardian.com/us-news/2026/oct/28/peptides-fda-health-human-services-department

Dated from the outlet's own feed. Check the original for its byline.

The Guardian · collected 2026-10-28 · by Associated Press

Quick Summary

FDA scientific staff members opposed a Trump administration plan pushed by Health Secretary Robert F Kennedy Jr, which aimed to ease access to unproven peptide drugs in the US wellness industry. The policy, posted online by HHS on Wednesday, would allow specialty pharmacies to sell several peptides without FDA approval, despite warnings from FDA scientists about potential safety risks. This move faces significant internal resistance as it could undermine the agency’s mission of regulating unapproved health products.
Written by AI on 2026-10-29, from this article's own text only (the story summary below draws on all the coverage).
See how they differ ↓

AI analysis

Story summary

As of October 28, 2026, the Trump administration's Department of Health and Human Services (HHS) allowed pharmacies to produce and sell six unapproved peptide drugs without FDA approval. This decision faced significant opposition from most FDA scientific staff members who warned it could undermine public health by exposing Americans to potentially unsafe substances. HHS stated that this move is intended to provide a regulated alternative for consumers seeking peptides, which have previously been available through the "gray market," often imported illegally from countries like China. The policy will be in effect while HHS works on formalizing a rule change and is set to take comments for two weeks before finalization.

Written for “RFK Jr Eases Access To Unapproved Peptides” on 2026-11-20, grounded in this article and the 13 other(s) covering the same event.

How they differ

11 outlets covered “RFK Jr Eases Access To Unapproved Peptides”.

What each outlet says

One AI summary per outlet of its latest article on this story, written from that article alone and checked against it. Open the article for the outlet's own words.

The GuardianThis outlet28 Oct

FDA scientific staff members opposed a Trump administration plan pushed by Health Secretary Robert F Kennedy Jr, which aimed to ease access to unproven peptide drugs in the US wellness industry. The policy, posted online by HHS on Wednesday, would allow specialty pharmacies to sell several peptides without FDA approval, despite warnings from FDA scientists about potential safety risks. This move faces significant…

FDA scientists opposed Trump administration’s move to ease peptide access (this article)
CBS News29 Oct

Adam Yamaguchi reports on Robert F. Kennedy Jr.’s efforts to encourage pharmacies to manufacture peptides that have not been approved by the FDA. The article focuses specifically on RFK Jr.’s advocacy for these unregulated substances, which are being promoted despite lacking official approval from regulatory authorities.

Inside RFK Jr.'s push for pharmacies to make non-FDA approved peptides →3 articles from CBS News on this story
ABC News (US)29 Oct

HHS announced that some wellness peptides will be available by prescription. The department will temporarily allow compounding pharmacies to provide six specific peptides through prescriptions. This announcement was made on October 29, 2026.

WATCH: HHS says some wellness peptides will be available by prescription →2 articles from ABC News (US) on this story
NBC News28 Oct

The Department of Health and Human Services has temporarily allowed compounding pharmacies to manufacture six unapproved peptides without legal repercussions while the FDA formalizes new rules for their production. These peptides include BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500, which are marketed as treatments for various health conditions but lack FDA approval due to insufficient safety and efficacy data…

RFK Jr. takes shortcut to make some peptides more widely available →
Toronto Star28 Oct

FDA scientific staff largely opposed a Trump administration plan aimed at easing access to unproven peptide drugs, despite pushback from Health Secretary Robert F. Kennedy Jr. This policy would allow specialty pharmacies to sell peptides without the FDA's rigorous safety and effectiveness review process, which are currently considered illegal drugs. Most FDA drug staffers warned that this could undermine the…

FDA scientists opposed the Trump administration's move to ease peptides access →
Time28 Oct

The U.S. Department of Health and Human Services announced on October 28 that it will not take enforcement action against licensed pharmacists who dispense six unapproved peptides to consumers. These peptides include BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500, which are short chains of amino acids injected for various health benefits, despite scientific uncertainty about their safety and efficacy. The policy…

The Peptide Rush Has Begun →
Show 5 more outlets
NPR29 Oct

The Trump administration's Department of Health and Human Services plans to relax restrictions on six unproven peptides, allowing small compounding pharmacies to produce them despite lacking FDA approval. This policy change supports wellness influencers and some clinicians who promote these peptides for various health issues like ulcerative colitis and insomnia, though evidence of their safety and effectiveness is…

Trump administration will allow pharmacies to make popular peptides →
The Independent29 Oct

Health Secretary Robert F. Kennedy Jr. announced a new policy allowing the widespread use of six unapproved peptide compounds, despite the FDA advising against their use due to potential risks. The Health and Human Services Department will not take enforcement action against those selling these peptides, arguing that easing access will provide patients with controlled alternatives while protecting safety through…

RFK Jr says he will allow widespread unapproved injections despite his FDA advising people not to use them →
BBC29 Oct

US Health Secretary Robert F Kennedy Jr has announced plans to relax restrictions on six unapproved peptides through compounding pharmacies, despite warnings from health experts about their potential risks due to insufficient human clinical trials and unknown long-term side effects. The draft regulation was published in the US Federal Register and will undergo a public comment period following its official…

US Health Secretary RFK Jr to expand access to unapproved peptides →
Reason29 Oct

HHS has established a new policy allowing pharmacies to produce and sell six specific peptides without FDA approval, aiming to provide a safer alternative to purchasing these substances from unregulated foreign sources. The decision is seen as a victory for peptide advocates and reflects frustration with FDA's slow processes, despite the lack of formal FDA endorsement or safety reviews for compounded drugs.

RFK Jr. Institutes Backdoor Approval of 6 Peptides →
New York Post29 Oct

The Trump administration recently relaxed regulations to allow easier access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr., despite opposition from the FDA’s scientific staff. The Department of Health and Human Services draft policy targets specific peptides used for wellness purposes such as muscle building and injury healing, allowing specialty pharmacies to sell them without facing…

Trump admin eases access to unproven peptides favored by RFK Jr. despite FDA opposition →

Where they agree and split

Framing

How the first headlines put it

Attributed to a source2
Stated as fact7
The headlines (9)

Some wellness peptides will become widely available, HHS says ABC News · attributed to a source

RFK Jr says he will allow widespread unapproved injections despite his FDA advising people not to use them The Independent · attributed to a source

RFK Jr. takes shortcut to make some peptides more widely available NBC News · stated as fact

FDA scientists opposed the Trump administration's move to ease peptides access Toronto Star · stated as fact

FDA scientists opposed Trump administration’s move to ease peptide access The Guardian · stated as fact

The Peptide Rush Has Begun Time · stated as fact

Trump administration will allow pharmacies to make popular peptides NPR · stated as fact

Dr. Jon LaPook explains why peptide sales are controversial CBS News · stated as fact

US Health Secretary RFK Jr to expand access to unapproved peptides BBC · stated as fact

The full story: what happened, how it changed, and all 14 articles →

Compared with similar articles

This article reads leans left and hedges 13% of its claims. Each row says how that neighbour differs.
Toronto Star
Leans left Hedges 5 of 33 claims Outlet record 64/100
New York Post
Hedges 6 of 46 claims Outlet record 66/100
NBC News
Hedges 4 of 19 claims Outlet record 78/100
TIME
Hedges 3 of 28 claims Outlet record 60/100
NPR
Leans right further right than this Hedges 4 of 30 claims Outlet record 60/100
The Independent
Hedges 1 of 12 claims Outlet record 59/100
CBS News
Hedges 3 of 22 claims Outlet record 67/100
BBC News
Leans right further right than this Hedges 1 of 20 claims Outlet record 65/100
Reason
Hedges 5 of 23 claims Outlet record 67/100
CBS News
Centre further right than this Hedges 1 of 3 claims Outlet record 67/100

Story

RFK Jr Eases Access To Unapproved Peptides
Politics · 14 article(s) covering the same event. Compare every outlet's account →
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
30
sentences that state something as happening or true
Uncertain
13%
4 of 30 hedged ("reportedly", "may", "according to")
Leaning
Leans left
of the writing, not the subject · beta estimate
Publisher signals
64/100
The Guardian's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
14
Politics
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-10-29 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

The Guardian · 2608 article(s) · 8 correction(s) detected
Running correction rate · 8 correction(s)

Who wrote this

Associated Press
797 article(s) here · 1 carrying a prediction
Published Nov. 20, 2026, 4:22 a.m. ET Russia launched missiles and drones across Kyiv overnight that killed three people, injured nine others and damaged bridges and transport infrastructure, local authorities said Friday. “We will respond to these attacks, and I want everyone to be clear about that,” Putin told reporters Thursday in China, where he attended a summit with the Chinese and US presidents.
Published Nov. 19, 2026, 10:16 p.m. ET The U.S. Army decided to delay Friday’s detonation of several tons of bomb-making chemicals in southeast Iowa after an outpouring of public concern that a cloud of lead dust could cause environmental contamination and health problems.
Kirsten Davies, chief information officer at the Defense Department, will fill the role, according to social media posts by several members of Trump’s cabinet.
Employees cannot realistically opt out of reading emails from their agency director, and the messages could coerce them to hide their own faith or feel pressure to adopt Rollins’ Christian faith, Thompson ruled.
Reinaldo Dennes, 70, was set to receive a lethal injection about an hour later at a prison in Texas and become the ninth person executed by that state this year.
Plans by the US army to detonate about 5 tons of bomb-making chemicals that have become unusable and might explode if moved have residents in south-east Iowa worried that a cloud of lead dust could cause environmental contamination and health problems.
The pardon comes after Manfred issued a sweeping decision last May that opened a pathway for Rose to be considered for baseball’s Hall of Fame.
The group agreed that Sanon, once in power, would award contracts to two Florida-based companies – Counter Terrorist Unit Federal Academy and Counter Terrorist Unit Security, collectively known as CTU – for infrastructure projects, security forces and military equipment, according to investigators.
The men would disable the trains at a planned location by busting the brakes, the indictment alleged, at which point the goods would be offloaded on to trucks.
“Our client will defend himself against the lawsuit,” Zverev’s lawyers said.
Wire or desk byline, not an individual reporter.
Also by Associated Press
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 797 articles by Associated Press →

Topics

Department of Health and Human Services FDA Food and Drug Administration HHS the United States

Subjects

FDA ORG · 15× HHS ORG · 10× Kennedy PERSON · 3× Americans NORP · 2× China GPE · 2× Department of Health and Human Services ORG · 1× Food and Drug Administration ORG · 1× Robert F Kennedy Jr PERSON · 1× the Associated Press ORG · 1× the United States GPE · 1×

Narrative

The FDA has warned Americans about safety risks of unproven peptides Many in the US who are using peptides today do not deal with a doctor or a pharmacy to get the injections, but often order vials online sold by chemical manufacturers based in China.
framing: assertive · carried by 1 article(s) · first seen 2026-10-29
The effort on peptides, driven almost entirely by HHS, faced overwhelming pushback among FDA drug staffers who warned it could undermine the agency’s longstanding mission of keeping unproven health products off the US market, according to the people familiar with its development.
2026-10-29 · The Guardian
FDA scientists opposed Trump administration’s move to ease peptide access · assertive framing

Claims (30 extracted, 4 hedged)

A plan to give people in the United States easier access to unproven peptide drugs favored by the US health secretary, Robert F Kennedy Jr, was opposed by most Food and Drug Administration scientific staff members, who had limited input in drafting the policy, according to six people familiar with its development. uncertain
who → give → development
The document posted online on Wednesday by Kennedy’s Department of Health and Human Services (HHS) covers a handful of injectable peptides promoted within the wellness industry for building muscle, healing injuries and boosting energy. asserted
document → post → energy
The effort on peptides, driven almost entirely by HHS, faced overwhelming pushback among FDA drug staffers who warned it could undermine the agency’s longstanding mission of keeping unproven health products off the US market, according to the people familiar with its development. uncertain
it → drive → development
The people spoke to the Associated Press on the condition of anonymity to discuss confidential government deliberations. asserted
people → speak → deliberations
An HHS spokesperson did not immediately respond to a request for comment. asserted
spokesperson → respond → comment
The policy directs the FDA not to take action against specialty pharmacies that sell a half-dozen wellness peptides, including BPC-157, TB-500 and KPV. asserted
that → direct → BPC-157
Under FDA rules, those chemicals would otherwise be considered illegal drugs because they have not gone through the agency’s rigorous review process for safety and effectiveness. asserted
they → consider → safety
Some peptides occur naturally in the human body, where they trigger hormones needed for growth, metabolism and healing. asserted
they → occur → growth
Drug companies have brought several to market as medications, including mainstay treatments for diabetes and weight loss. asserted
companies → bring → diabetes
But the chemicals subject to the new policy haven’t been approved as safe and effective by the FDA. asserted
chemicals → approve → FDA
Kennedy has called himself a “big fan” of peptides and recently described using BPC-157 to treat a muscle injury. asserted
Kennedy → call → injury
The new document represents a step back from HHS’s original plans, according to two of the people who discussed its development. uncertain
who → represent → development
HHS officials initially wanted the FDA to draft an official regulation that would add BPC-157 and other peptides to a list of drug substances deemed safe for use by compounding pharmacies, specialty businesses that make customized medications. asserted
that → want → medications
FDA officials warned that the agency’s scientific staffers had major safety concerns and would not support a regulation deeming them safe. asserted
them → warn → regulation
HHS officials moved to a different approach that directs the FDA not to enforce its rules against pharmacies that compound the substances. asserted
that → move → substances
FDA staffers ultimately provided technical assistance in drafting the HHS plan, including guardrails intended to improve safety, such as requiring pharmacies to use peptide ingredients from FDA-registered factories. asserted
staffers → provide → factories
Decisions over compounding have long rested with the FDA, not HHS. asserted
Decisions → rest → FDA
Kennedy has said that US compounding pharmacies must be allowed to sell peptides because Americans are turning to “gray market” products imported from China and other countries. asserted
Americans → say → China
Decisions about regulating peptides and compounding pharmacies have almost always come from the FDA, which has an office dedicated to protecting US consumers from unsafe or poor-quality compounded drugs. asserted
which → regulate → drugs
The issue of compounding safety became a greater focus for the FDA after a deadly outbreak of fungal meningitis in 2012 was linked to contaminated injections from a Massachusetts compounding pharmacy. asserted
outbreak → become → pharmacy
Once a niche business, compounding has grown into a multibillion-dollar industry, providing customized medications to doctors, clinics and hospitals. asserted
compounding → grow → doctors
It’s extremely rare for HHS to take the lead in drafting policies over the compounding industry, former FDA officials said. asserted
officials → ’ → industry
However, federal law technically gives HHS authority over essentially all drug regulations, which are then delegated to the FDA. asserted
which → give → FDA
The FDA has warned Americans about safety risks of unproven peptides Many in the US who are using peptides today do not deal with a doctor or a pharmacy to get the injections, but often order vials online sold by chemical manufacturers based in China. asserted
who → warn → China
Peptide sellers often try to skirt US regulations by labeling their products as “for research use only” because the FDA does not regulate research chemicals. asserted
FDA → try → chemicals
In 2023, the FDA added more than a dozen peptides, including BPC-157 and TB-500, to its list of substances that should not be compounded due to risks of allergic reactions, kidney damage and tumor growth. asserted
that → add → reactions
At a meeting in July, FDA staffers reiterated that more than half a dozen peptides brought forward for reconsideration remained unproven in terms of safety and effectiveness. asserted
peptides → reiterate → safety
The new policy from HHS avoids a direct confrontation with FDA staffers because it only directs the FDA not to enforce certain rules. asserted
it → avoid → rules
HHS ultimately included several safety measures suggested by FDA staffers, according to two of the people. uncertain
HHS → include → people
Besides sourcing ingredients from FDA-registered facilities, compounders will be directed to collect information on side effects for safety analysis and verify the chemical identity of peptides. asserted
compounders → source → peptides
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support